Maladies peptiques [Acid related diseases progress in 2007].


Autoria(s): Vouillamoz D.; Jornod P.; Viani F.; Nichita C.; Dorta G.
Data(s)

2008

Resumo

The treatment of reflux disease did not changed. PPI treatment remains the first line treatment and surgery a second line treatment. The effect of surgery in reflux disease reduces and, after ten years, a part of the operated patients needs PPI again. The triple therapy is the treatment of choice of Helicobacter pylori infection. Patients with persistent Helicobacter pylori infection, after a first treatment, should be treated with a sequential treatment. PPI are effective in the prevention of gastroduodenal lesions and in the treatment of dyspeptic symptoms during NSAID treatment. IPP should be given to all patients presenting dyspeptic symptoms under NSAID or COX-2 administration.

Identificador

http://serval.unil.ch/?id=serval:BIB_413B6D610D71

isbn:1660-9379 (Print)

pmid:18335884

Idioma(s)

fr

Fonte

Revue Médicale Suisse, vol. 4, no. 141, pp. 190-194

Palavras-Chave #Esophagitis, Peptic/drug therapy; Esophagitis, Peptic/therapy; Gastroesophageal Reflux/drug therapy; Gastroesophageal Reflux/therapy; Helicobacter Infections/drug therapy; Helicobacter pylori; Humans; Stomach Diseases/drug therapy; Stomach Diseases/microbiology
Tipo

info:eu-repo/semantics/review

article